Literature DB >> 27235117

Silencing of ST6GalNAc I suppresses the proliferation, migration and invasion of hepatocarcinoma cells through PI3K/AKT/NF-κB pathway.

Xiao Yu1, Qiang Wu2, Liping Wang2, Yujie Zhao2, Qingqing Zhang1, Qingtao Meng3, Shujing Wang4.   

Abstract

ST6GalNAc I is the major Sialyl-Tn antigen (STn) synthase that is highly correlated with tumor invasion and metastasis. However, the roles and molecular mechanisms by which ST6GalNAc I mediates the malignant phenotypes of hepatocarcinoma cells still remain poorly unknown. In this study, we investigated the expression of STn and ST6GalNAc I in mouse hepatocarcinoma cell lines Hca-F, Hca-P, and Hepa1-6, which have different metastatic potential, as compared with normal mouse liver cell line IAR-20. The results showed that the expression of ST6GalNAc I and STn in Hca-F and Hca-P cells was much higher than that in Hepa1-6 and IAR20 cells. Knockdown of ST6GalNAc I by shRNA in Hca-F cells significantly decreased the expression of STn and inhibited the growth of tumor cells in vitro and in vivo. This reduction of ST6GalNAc I expression also led to the decreased migration and invasion of Hca-F cells. Furthermore, we found that ST6GalNAc I knockdown inhibited the expression levels of PI3k, p-Akt473, p-Akt308, NF-κB, and their downstream molecules. Together, our results suggest a role of ST6GalNAc I in promoting the growth and invasion of hepatocarcinoma cells through regulating PI3K/AKT signaling, and ST6GalNAc I might be a promising marker for the prognosis and therapy of hepatocarcinoma.

Entities:  

Keywords:  Hepatocarcinoma; Invasion; Migration; Proliferation; ST6GalNAc I; STn

Mesh:

Substances:

Year:  2016        PMID: 27235117     DOI: 10.1007/s13277-016-5086-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  Functional expression of CXC chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability.

Authors:  Haiying Chu; Huimin Zhou; Yanli Liu; Xinyu Liu; Yichuan Hu; Jianing Zhang
Journal:  Int J Biochem Cell Biol       Date:  2006-08-14       Impact factor: 5.085

2.  Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells.

Authors:  Mylène A Carrascal; Paulo F Severino; M Guadalupe Cabral; Mariana Silva; José Alexandre Ferreira; Fernando Calais; Hermínia Quinto; Cláudia Pen; Dário Ligeiro; Lúcio Lara Santos; Fabio Dall'Olio; Paula A Videira
Journal:  Mol Oncol       Date:  2014-03-06       Impact factor: 6.603

3.  Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery.

Authors:  Diana Campos; Daniela Freitas; Joana Gomes; Ana Magalhães; Catharina Steentoft; Catarina Gomes; Malene B Vester-Christensen; José Alexandre Ferreira; Luis P Afonso; Lúcio L Santos; João Pinto de Sousa; Ulla Mandel; Henrik Clausen; Sergey Y Vakhrushev; Celso A Reis
Journal:  Mol Cell Proteomics       Date:  2015-03-26       Impact factor: 5.911

4.  Caveolin-1 up-regulates ST6Gal-I to promote the adhesive capability of mouse hepatocarcinoma cells to fibronectin via FAK-mediated adhesion signaling.

Authors:  Shengjin Yu; Lijun Zhang; Nanyang Li; Jianhui Fan; Linhua Liu; Jianing Zhang; Shujing Wang
Journal:  Biochem Biophys Res Commun       Date:  2012-09-26       Impact factor: 3.575

5.  STn and prognosis in breast cancer.

Authors:  M Leivonen; S Nordling; J Lundin; K von Boguslawski; C Haglund
Journal:  Oncology       Date:  2001       Impact factor: 2.935

6.  Competition between core-2 GlcNAc-transferase and ST6GalNAc-transferase regulates the synthesis of the leukocyte selectin ligand on human P-selectin glycoprotein ligand-1.

Authors:  Chi Y Lo; Aristotelis Antonopoulos; Rohitesh Gupta; Jun Qu; Anne Dell; Stuart M Haslam; Sriram Neelamegham
Journal:  J Biol Chem       Date:  2013-04-02       Impact factor: 5.157

7.  RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells.

Authors:  Fumito Tamura; Yasushi Sato; Masahiro Hirakawa; Makoto Yoshida; Michihiro Ono; Takahiro Osuga; Yutaka Okagawa; Naoki Uemura; Yohei Arihara; Kazuyuki Murase; Yutaka Kawano; Satoshi Iyama; Kohichi Takada; Tsuyoshi Hayashi; Tsutomu Sato; Koji Miyanishi; Masayoshi Kobune; Rishu Takimoto; Junji Kato
Journal:  Gastric Cancer       Date:  2014-12-23       Impact factor: 7.370

8.  Expression profile of mucin-associated sialyl-Tn antigen in Chinese patients with different colorectal lesions (adenomas, carcinomas).

Authors:  Feng Xu; Cuizhen Fan; Shanshan Fan; Fuquan Liu; Tao Wen; Guangyu An; Guosheng Feng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 9.  Galectin-Binding O-Glycosylations as Regulators of Malignancy.

Authors:  Charles J Dimitroff
Journal:  Cancer Res       Date:  2015-07-29       Impact factor: 12.701

10.  Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.

Authors:  José Alexandre Ferreira; Paula A Videira; Luís Lima; Sofia Pereira; Mariana Silva; Mylène Carrascal; Paulo F Severino; Elisabete Fernandes; Andreia Almeida; Céu Costa; Rui Vitorino; Teresina Amaro; Maria J Oliveira; Celso A Reis; Fabio Dall'Olio; Francisco Amado; Lúcio Lara Santos
Journal:  Mol Oncol       Date:  2013-03-21       Impact factor: 6.603

View more
  6 in total

1.  Cross-talk between Colon Cells and Macrophages Increases ST6GALNAC1 and MUC1-sTn Expression in Ulcerative Colitis and Colitis-Associated Colon Cancer.

Authors:  Michael Kvorjak; Yasmine Ahmed; Michelle L Miller; Raahul Sriram; Claudia Coronnello; Jana G Hashash; Douglas J Hartman; Cheryl A Telmer; Natasa Miskov-Zivanov; Olivera J Finn; Sandra Cascio
Journal:  Cancer Immunol Res       Date:  2019-12-12       Impact factor: 11.151

Review 2.  Mucins as anti-cancer targets: perspectives of the glycobiologist.

Authors:  Inka Brockhausen; Jacob Melamed
Journal:  Glycoconj J       Date:  2021-03-11       Impact factor: 2.916

3.  O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer.

Authors:  Sofia N Santos; Mara S Junqueira; Guilherme Francisco; Manuel Vilanova; Ana Magalhães; Marcelo Dias Baruffi; Roger Chammas; Adrian L Harris; Celso A Reis; Emerson S Bernardes
Journal:  Oncotarget       Date:  2016-12-13

4.  Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.

Authors:  David A Eavarone; Linah Al-Alem; Alexey Lugovskoy; Jillian M Prendergast; Rawan I Nazer; Jenna N Stein; Daniel T Dransfield; Jeff Behrens; Bo R Rueda
Journal:  PLoS One       Date:  2018-07-27       Impact factor: 3.240

Review 5.  Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?

Authors:  Silvia Pietrobono; Barbara Stecca
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

6.  ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation.

Authors:  Imayavaramban Lakshmanan; Sanjib Chaudhary; Raghupathy Vengoji; Parthasarathy Seshacharyulu; Satyanarayana Rachagani; Joseph Carmicheal; Rahat Jahan; Pranita Atri; Ramakanth Chirravuri-Venkata; Rohitesh Gupta; Saravanakumar Marimuthu; Naveenkumar Perumal; Sanchita Rauth; Sukhwinder Kaur; Kavita Mallya; Lynette M Smith; Subodh M Lele; Moorthy P Ponnusamy; Mohd W Nasser; Ravi Salgia; Surinder K Batra; Apar Kishor Ganti
Journal:  Mol Oncol       Date:  2021-05-01       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.